Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed Quote. Delayed London Stock Exchange - 09/24 11:35:14 am
8845 GBX   +2.04%
09/24Health Care Stocks Retreat Friday
MT
09/24Eurostoxx 50 : European stocks slip on Evergrande woes, weak German business morale
RE
09/24European ADRs Move Lower in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : NetScientific's unit signs deal to sell AstraZeneca's COVID-19 test

06/07/2021 | 02:55am EDT
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration

(Reuters) - British life sciences company NetScientific Plc said on Monday that one of its subsidiaries has entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a COVID-19 test.

NetScientific's wholly-owned unit ProAxsis Ltd will look after completing validation and global commercialisation of AstraZeneca's SARS-CoV-2 serology ELISA and, in return, the Anglo-Swedish drugmaker will receive a royalty fee on future global net sales of the assay, the company said.

The ELISA, or enzyme-linked immunosorbent assay that is developed by an internal research team at AstraZeneca, is a highly sensitive and specific blood test that collects samples from a finger prick. AstraZeneca said the test will be well-suited for antibody analyses in large populations.

"The assay could, if fully validated, potentially attract a substantial market," NetScientific Chief Executive Officer Ilian Iliev said in a statement.

NetScientific holds 95% stake in ProAxsis on a fully diluted basis.

(Reporting by Vishwadha Chander in Bengaluru; editing by Uttaresh.V)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.04% 8845 Delayed Quote.20.77%
NETSCIENTIFIC PLC 3.67% 127 Delayed Quote.173.12%
All news about ASTRAZENECA PLC
09/24Health Care Stocks Retreat Friday
MT
09/24Eurostoxx 50 : European stocks slip on Evergrande woes, weak German business morale
RE
09/24European ADRs Move Lower in Friday Trading
MT
09/24ASTRAZENECA : Receives a Buy rating from Barclays
MD
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24IMPERIAL COLLEGE LONDON : Imperial RNA technology to be developed by VaxEquity with AstraZ..
AQ
09/24DEPARTMENT OF HEALTH AND SOCIAL CARE : check the rules for travel to England from abroad
AQ
09/24ASTRAZENECA : Lynparza in combination with abiraterone significantly delayed disease progr..
AQ
09/24ASTRAZENECA : LYNPARZA« (olaparib) in combination with abiraterone significantly delayed d..
BU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 33,8x
Yield 2021 2,33%
Capitalization 187 B 187 B -
EV / Sales 2021 5,98x
EV / Sales 2022 4,85x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 120,91 $
Average target price 136,24 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC20.77%187 304
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037